This pathway applies only to uncomplicated cases meeting local protocol criteria
D 66 , 213221 (2010) Vagin, A
You have severe gastrointestinal conditions that make tolerating GLP-1 class medications difficult
(NEJM, 2023) showed approximately 24% mean weight reduction with Retatrutide at 12 mg at 48 weeks, while Semaglutide demonstrated approximately 15% at 2.4 mg weekly in the STEP trials again, these are cross-trial figures drawn from studies with different designs and populations, and should be treated as indirect
Common GLP-1 receptor agonist medications include semaglutide drugs such as Ozempic, Wegovy, and Rybelsus, as well as tirzepatide medications including Mounjaro and Zepbound
Retatrutide addresses these challenges through multiple pathways simultaneously